Recurrent AKT mutations in human cancers: functional consequences and effects on drug sensitivity
Precision oncology trials based on tumor gene sequencing depend on robust knowledge about the phenotypic consequences of the genetic variants identified in patients' tumors. Mutations in AKT1-3 occur in 3-5% of human cancers. Although a single hotspot mutation, E17K, is the most common, well ch...
Main Authors: | , |
---|---|
Format: | Online |
Language: | English |
Published: |
Impact Journals LLC
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826202/ |